验证数据展示
产品信息
12892-1-PBS targets TDP-43 (C-terminal) in WB, IHC, IF/ICC, IF-Fro, FC (Intra), IP, ELISA applications and shows reactivity with human, mouse, rat samples.
经测试应用 | WB, IHC, IF/ICC, IF-Fro, FC (Intra), IP, ELISA Application Description |
经测试反应性 | human, mouse, rat |
免疫原 | fusion protein 种属同源性预测 |
宿主/亚型 | Rabbit / IgG |
抗体类别 | Polyclonal |
产品类型 | Antibody |
全称 | TAR DNA binding protein |
别名 | TDP 43, TARDBP, TDP43, TDP-43, TAR DNA-binding protein 43 |
计算分子量 | 43 kDa |
观测分子量 | 43-45 kDa, 35 kDa |
GenBank蛋白编号 | BC001487 |
基因名称 | TDP-43 |
Gene ID (NCBI) | 23435 |
RRID | AB_2200505 |
偶联类型 | Unconjugated |
形式 | Liquid |
纯化方式 | Antigen affinity purification |
UNIPROT ID | Q13148 |
储存缓冲液 | PBS only , pH 7.3 |
储存条件 | Store at -80°C. The product is shipped with ice packs. Upon receipt, store it immediately at -80°C |
背景介绍
Transactivation response (TAR), DNA-binding protein of 43 kDa (also known as TARDBP or TDP-43), was first isolated as a transcriptional inactivator binding to the TAR DNA element of the HIV-1 virus. Neumann et al. (2006) found that a hyperphosphorylated, ubiquitinated, and cleaved form of TARDBP, known as pathologic TDP-43, is the major component of the tau-negative and ubiquitin-positive inclusions that characterize amyotrophic lateral sclerosis (ALS) and the most common pathological subtype of frontotemporal lobar degeneration (FTLD-U). 12892-1-AP is a rabbit polyclonal antibody raised against the C-terminal amino acids of human TDP-43. This antibody recognizes the cleavage product of 20-30 kDa in addition to the native and phosphorylated forms of TDP-43. Immunohistochemical analyses of TDP-43 using this antibody detect both normal diffuse nuclear staining and insoluble inclusions in pathologic tissues. Various forms of TDP-43 exist, including 18-35 kDa of cleaved C-terminal fragments, 45-50 kDa phosphoprotein, 55 kDa glycosylated form, 75 kDa hyperphosphorylated form, and 90-300 kDa cross-linked form. (17023659,19823856,21666678,22193176)
Recently TDP-43 has been reported to be overexpressed in triple negative breast cancer (TNBC) and it may be a potential target for TNBC diagnosis and drug design. (29581274)